References
- Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis [Internet]. 2023;83(1):15-29. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard-2023-224762
- Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus [Internet]. 2016;25(7):727–734. Available from: http://journals.sagepub.com/doi/10.1177/0961203315627202
- Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, et al. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med [Internet]. 2016;3(1):e000157. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2016-000157
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet [Internet]. 1999;354(9194):1932–1939. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673699052460
- Moreland LW. Etanercept therapy in rheumatoid arthritis. Ann Intern Med [Internet]. 1999;130(6):478. Available from: http://annals.org/article.aspx?doi=10.7326/0003-4819-130-6-199903160-00004
- Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med [Internet]. 2020;382(3):211–221. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1912196
- Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi: 10.1002/art.30613
- Felten R, Scherlinger M, Mertz P, et al. New biologics and targeted therapies in systemic lupus:from new molecular targets to new indications. A systematic review. Joint Bone Spine [Internet]. 2023;90(2):105523. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1297319X23000027
- Tobón GJ, Izquierdo JH, Ca C. B lymphocytes: development, tolerance, and their role in autoimmunity—focus on systemic lupus erythematosus. Autoimmune Dis [Internet]. 2013;2013:1–17. Available from: http://www.hindawi.com/journals/ad/2013/827254/
- Yap DYH, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis—role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci [Internet]. 2019;20(24):6231. Available from: https://www.mdpi.com/1422-0067/20/24/6231
- Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol [Internet]. 2009;9(7):491–502. Available from: https://www.nature.com/articles/nri2572
- Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9. doi: 10.3389/fimmu.2018.02285
- Steri M, Orrù V, Idda ML, et al. Overexpression of the cytokine baff and autoimmunity risk. N Engl J Med [Internet]. 2017;376(17):1615–1626. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1610528
- Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum [Internet]. 2008;58(8):2453–2459. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.23678
- Hoffmann FS, Kuhn P-H, Laurent SA, et al. The immunoregulator soluble taci is released by adam10 and reflects B cell activation in autoimmunity. J Immunol [Internet]. 2015;194(2):542–552. Available from: https://journals.aai.org/jimmunol/article/194/2/542/108733/The-Immunoregulator-Soluble-TACI-Is-Released-by
- Kreuzaler M, Rauch M, Salzer U, et al. Soluble BAFF levels inversely correlate with peripheral b cell numbers and the expression of baff receptors. J Immunol [Internet]. 2012;188(1):497–503. Available from: https://journals.aai.org/jimmunol/article/188/1/497/39444/Soluble-BAFF-Levels-Inversely-Correlate-with
- Yan M, Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol [Internet]. 2001;2(7):638–643. Available from: https://www.nature.com/articles/ni0701_638
- Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet [Internet]. 2011;377(9767):721–731. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673610613542
- Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med [Internet]. 2020;383(12):1117–1128. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2001180
- Gatto M, Saccon F, Zen M, et al. Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real‐life setting. Arthritis & Rheumatol [Internet]. 2020;72(8):1314–1324. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41253
- Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun [Internet]. 2018;86:1–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841117304389
- Trentin F, Gatto M, Zen M, et al. Effectiveness, Tolerability, and safety of belimumab in patients with refractory sle: a review of observational clinical-practice-based studies. Clin Rev Allergy Immunol [Internet]. 2018;54(2):331–343. Available from: https://doi.org/10.1007/s12016-018-8675-2
- Gatto M, Saccon F, Andreoli L, et al. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRliSS-LN). Results from a large, nationwide, multicentric cohort. J Autoimmun [Internet]. 2021;124:102729. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841121001372
- Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol [Internet]. 2015;33(4):449–456. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26053285
- Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol [Internet]. 2016;12(6):367–372. Available from: https://www.nature.com/articles/nrrheum.2016.18
- Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum baff levels are associated with rising anti–double‐stranded DNA antibody levels and disease flare following b cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum [Internet]. 2013;65(10):2672–2679. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.38074
- Atisha‐Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol [Internet]. 2021;73(1):121–131. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41466
- Shipa M, Embleton-Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus. Ann Intern Med [Internet]. 2021 [cited 2023 Oct 12];174(12):1647–1657. Available from: https://www.acpjournals.org/doi/10.7326/M21-2078
- Dall’era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase ib, double‐blind, placebo‐controlled, dose‐escalating trial. Arthritis Rheum [Internet]. 2007;56(12):4142–4150. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.23047
- Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol [Internet]. 2018;70(2):266–276. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40360
- Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis [Internet]. 2015;74(11):2006–2015. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2013-205067
- Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus [Internet]. 2009;18(6):547–555. Available from: http://journals.sagepub.com/doi/10.1177/0961203309102803
- Di W, Jing L, Dong X, et al. Telitacicept, a human recombinant fusion protein targeting b lymphocyte stimulator (blys) and a proliferation-inducing ligand (April), in systemic lupus erythematosus (sle): results of a phase 3 study. ACR meeting abstracts [Internet]. Arthritis Rheumatol. [cited 2023 Oct 12]. Available from: https://acrabstracts.org/abstract/telitacicept-a-human-recombinant-fusion-protein-targeting-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-in-systemic-lupus-erythematosus-sle-results-of-a-phase-3-study/
- Choi YS, Kageyama R, Eto D, et al. ICOS receptor instructs t follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. Immunity [Internet]. 2011;34(6):932–946. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1074761311001853
- Zhang M, Lee F, Knize A, et al. Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol [Internet]. 2019;37:906–914. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30789152
- Abuqayyas L, Chen P, dos Santos MT, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic properties of rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase i clinical trials. Clin Pharmacol Ther [Internet]. 2023;114:371–380. Available from: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2929
- Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol [Internet]. 2022;18:575–590. Available from: https://www.nature.com/articles/s41584-022-00826-z
- Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol [Internet]. 2010;6(6):339–347. Available from: https://www.nature.com/articles/nrrheum.2010.64
- Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus [Internet]. 2000;9(9):664–671. Available from: http://journals.sagepub.com/doi/10.1191/096120300674499064
- Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum [Internet]. 1982;25(4):401–406. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.1780250407
- Niewold TB, Hua J, Lehman TJA, et al. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun [Internet]. 2007;8(6):492–502. Available from: https://www.nature.com/articles/6364408
- Sarzi-Puttini P, Atzeni F, Iaccarino L, et al. Environment and systemic lupus erythematosus: an overview. Autoimmunity [Internet]. 2005;38(7):465–472. Available from: http://www.tandfonline.com/doi/full/10.1080/08916930500285394
- Harley ITW, Niewold TB, Stormont RM, et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:1–11. doi: 10.1155/2010/706825
- Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon‐α activity in systemic lupus erythematosus patients. Arthritis Rheum [Internet]. 2008;58(8):2481–2487. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.23613
- Harley JB, Alarcón-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet [Internet]. 2008;40(2):204–210. Available from: https://www.nature.com/articles/ng.81
- Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus from the national institute of arthritis and musculoskeletal and skin diseases Available from: www.nejm.org
- Castellano G, Cafiero C, Divella C, et al. Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther. 2015;17(1):17. doi: 10.1186/s13075-015-0588-3
- LaFleur DW, Nardelli B, Tsareva T, et al. Interferon-κ, a novel type i interferon expressed in human keratinocytes. J Biol Chem [Internet]. 2001;276(43):39765–39771. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021925820600400
- Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1
- McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum [Internet]. 2012;64(11):3666–3676. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.34632
- Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMab interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis [Internet]. 2016;75(1):196–202. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2014-206090
- Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70(11):1905–1913. doi: 10.1136/ard.2010.144485
- Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti–interferon‐α monoclonal antibody, in systemic lupus erythematosus: a phase i randomized, controlled, dose‐escalation study. Arthritis Rheum [Internet]. 2013;65(4):1011–1021. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.37824
- Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis [Internet]. 2016;75(11):1909–1916. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-208562
- Jordan J, Benson J, Chatham WW, et al. First-in-human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial. Lancet Rheumatol [Internet]. 2020;2(10):e613–e622. Available from: https://linkinghub.elsevier.com/retrieve/pii/S266599132030223X
- Zagury D, Le Buanec H, Mathian A, et al. IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci [Internet]; 2009;106:5294–5299. Available from: https://pnas.org/doi/full/10.1073/pnas.0900615106
- Mathian A, Amoura Z, Adam E, et al. Active immunisation of human interferon α transgenic mice with a human interferon α kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2011;70(6):1138–1143. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard.2010.141101
- Lauwerys BR, Hachulla E, Spertini F, et al. Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid. Arthritis Rheum [Internet]. 2013;65(2):447–456. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.37785
- Houssiau FA, Thanou A, Mazur M, et al. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis [Internet]. 2020;79(3):347–355. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2019-216379
- McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23–IL-17 immune pathway. Trends Immunol [Internet]. 2006;27(1):17–23. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1471490605002814
- Iwakura Y. The IL-23/IL-17 axis in inflammation. J Clin Investigation [Internet]. 2006;116(5):1218–1222. Available from: http://www.jci.org/cgi/doi/10.1172/JCI28508
- Larosa M, Zen M, Gatto M, et al. IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med (Maywood) [Internet]. 2019;244(1):42–51. Available from: http://journals.sagepub.com/doi/10.1177/1535370218824547
- Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis [Internet]. 2020;79(6):700.1–712. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217159
- Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis [Internet]. 2023;82(1):19–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/36270658
- Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis [Internet]. 2022;16(1):2–17. Available from: https://academic.oup.com/ecco-jcc/article/16/1/2/6390052
- Chen D-Y, Chen Y-M, Wen M-C, et al. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus [Internet]. 2012;21(13):1385–1396. Available from: http://journals.sagepub.com/doi/10.1177/0961203312457718
- Zickert A, Amoudruz P, Sundström Y, et al. IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol [Internet]. 2015;16(1):7. Available from:https://bmcimmunol.biomedcentral.com/articles/10.1186/s12865-015-0070-7
- Talaat RM, Mohamed SF, Bassyouni IH, et al. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine [Internet]. 2015;72(2):146–153. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1043466615000046
- Paquissi FC, Abensur H. The Th17/IL-17 axis and kidney diseases, with focus on lupus nephritis. Front Med (Lausanne) [Internet]. 2021;8. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2021.654912/full
- Rahmé Z, Franco C, Cruciani C, et al. Characterization of serum cytokine profiles of patients with active lupus nephritis. Int J Mol Sci [Internet]. 2023;24(19):14883. Available from: https://www.mdpi.com/1422-0067/24/19/14883
- van Vollenhoven Rf, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet [Internet]. 2018;392(10155):1330–1339. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618321676
- van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2022;81(11):1556–1563. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard-2022-222858
- Satoh Y, Nakano K, Yoshinari H, et al. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus [Internet]. 2018;27(7):1202–1206. Available from: http://journals.sagepub.com/doi/10.1177/0961203318762598
- Costa R, Antunes P, Salvador P, et al. Secukinumab on refractory lupus nephritis. Cureus. Available from: https://www.cureus.com/articles/63741-secukinumab-on-refractory-lupus-nephritis
- Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus [Internet]. 2004;13(5):339–343. Available from: http://journals.sagepub.com/doi/10.1191/0961203304lu1023oa
- Van Snick J. Interleukin-6: an overview. Annu Rev Immunol [Internet]. 1990;8(1):253–278. Available from: https://www.annualreviews.org/doi/10.1146/annurev.iy.08.040190.001345
- Kaur S, Bansal Y, Kumar R, et al. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem [Internet]. 2020;28(5):115327. Available from: https://linkinghub.elsevier.com/retrieve/pii/S096808961931692X
- Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med [Internet]. 2017;377(4):317–328. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1613849
- Maini RN, Taylor PC, Szechinski J, et al. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum [Internet]. 2006;54(9):2817–2829. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.22033
- Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med [Internet]. 2023;389(14):1263–1272. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2303452
- Chun H-Y, Chung J-W, Kim H-A, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol [Internet]. 2007;27(5):461–466. Available from: https://doi.org/10.1007/s10875-007-9104-0
- Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol [Internet]. 1998;112(3):397–402. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9649207
- Ryffel B, Car BD, Gunn H, et al. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am J Pathol [Internet]. 1994;144(5):927–937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8178944
- Chaoyi M, Shrestha B, Hui L, et al. Tocilizumab therapy for persistent high-grade fever in systemic lupus erythematosus: two cases and a literature review. J Int Med Res [Internet]. 2022;50(3):030006052210885. Available from: http://journals.sagepub.com/doi/10.1177/03000605221088558
- Iwai A, Naniwa T, Tamechika S, et al. Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis. Mod Rheumatol [Internet]. 2017;27(3):529–532. Available from: https://academic.oup.com/mr/article/27/3/529-532/6302401
- Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study. Arthritis Rheum [Internet]. 2010;62(2):542–552. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.27221
- Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2013;72(1):118–128. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2012-201310
- Jin B, Odongo S, Radwanska M, et al. NANOBODIES®: a review of diagnostic and therapeutic applications. IJMS [Internet]. 2023;24(6):5994. Available from: https://www.mdpi.com/1422-0067/24/6/5994
- Wu B, Zhao L, Zhang X. CXCR4 and CXCR5 orchestrate dynamic germinal center reactions and may contribute to the pathogenesis of systemic lupus erythematosus. Cell Mol Immunol [Internet]. 2019;16(8):724–726. Available from: https://www.nature.com/articles/s41423-019-0244-y
- Bombardieri M, Barone F, Lucchesi D, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in c57bl/6 mice. J Immunol [Internet]. 2012;189(7):3767–3776. Available from: https://journals.aai.org/jimmunol/article/189/7/3767/86439/Inducible-Tertiary-Lymphoid-Structures
- Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren’s syndrome. Arthritis Rheum [Internet]. 2005;52(6):1773–1784. Available from: https://onlinelibrary.wiley.com/doi/10.1002/art.21062
- Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. Huizinga T, editor. PLOS Med [Internet]. 2009;6:e1. Available from: https://doi.org/10.1371/journal.pmed.0060001
- Manzo A, Paoletti S, Carulli M, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol [Internet]. 2005;35(5):1347–1359. Available from: https://onlinelibrary.wiley.com/doi/10.1002/eji.200425830
- Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol [Internet]. 2011;186(3):1849–1860. Available from: https://journals.aai.org/jimmunol/article/186/3/1849/84962/In-Situ-B-Cell-Mediated-Immune-Responses-and
- He DN, Chen WL, Long KX, et al. Association of serum cxcl13 with intrarenal ectopic lymphoid tissue formation in lupus nephritis. J Immunol Res [Internet]. 2016;2016:1–8. Available from: https://www.hindawi.com/journals/jir/2016/4832543/
- Steinmetz OM, Velden J, Kneissler U, et al. Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int [Internet]. 2008;74(4):448–457. Available from 10.1038/ki.2008.191
- De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol [Internet]. 2015;15(3):137–148. Available from: https://www.nature.com/articles/nri3804
- Cohen S, Beebe J, Chindalore V, et al. AB0511 AB0511 A phase 1, randomised, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety. In: Pharmacokinetics and pharmacodynamics of pf-06835375 in patients with seropositive systemic lupus erythematosus or rheumatoid arthritis. Scientific abstracts [internet]. BMJ Publishing Group Ltd and European League Against Rheumatism; 2023. p. 1450.2–1450. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2023-eular.95
- Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol [Internet]. 2011;11(2):119–130. Available from: https://www.nature.com/articles/nri2916
- Kolios AGA, Tsokos GC, Klatzmann D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat Rev Rheumatol [Internet]. 2021;17(12):749–766. Available from: https://www.nature.com/articles/s41584-021-00707-x
- Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis [Internet]. 2019;78(2):209–217. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-214229
- Humrich JY, Morbach H, Undeutsch R, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Nat Acad Sci [Internet]; 2010;107:204–209. Available from: https://pnas.org/doi/full/10.1073/pnas.0903158107
- von Spee-Mayer C, Siegert E, Abdirama D, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2016;75(7):1407–1415. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2015-207776
- Humrich JY, Cacoub P, Rosenzwajg M, et al. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis [Internet]. 2022;81(12):1685–1694. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard-2022-222501
- Visweswaraiah J, Sampson E, Petaipimol P, et al. OP0023 generation of PT101, a highly selective IL-2 mutein for treatment of autoimmune diseases. Ann Rheum Dis [Internet]. 2021;80(Suppl 1):13.1–13. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2021-eular.2097
- Sarra M, Monteleone G. Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus. J Biomed Biotechnol [Internet]. 2010. 1–6. Available from: http://www.hindawi.com/journals/bmri/2010/294582/
- Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates with t cell and b cell subset Alterations in systemic lupus Erythematosus. J Rheumatol [Internet]. 2012;39:1819–1828. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.120468
- Nakou M, Papadimitraki ED, Fanouriakis A, et al. Interleukin-21 is increased in active systemic lupus erythematosus patients and contributes to the generation of plasma B cells. Clin Exp Rheumatol [Internet]. 2013;31(2):172–179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23137515
- Sawalha AH, Kaufman KM, Kelly JA, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2008;67(4):458–461. Available from: https://ard.bmj.com/lookup/doi/10.1136/ard.2007.075424
- Hussaini A, Mukherjee R, Berdieva DM, et al. A double‐blind, phase i, single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of bos161721 in healthy subjects. Clin Transl Sci [Internet]. 2020;13(2):337–344. Available from: https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12715
- Biswas S, Bieber K, Manz RA. IL-10 revisited in systemic lupus erythematosus. Front Immunol [Internet]. 2022;13. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.970906/full
- Godsell J, Rudloff I, Kandane-Rathnayake R, et al. Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus. Sci Rep [Internet]. 2016;6(1):34604. Available from: https://www.nature.com/articles/srep34604
- Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus [Internet]. 2012;21(14):1492–1496. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23042821
- Ghirardello A, Doria A, Zampieri S, et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun [Internet]. 2004;22(3):235–240. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841103001975
- Gatto M, Saccon F, Zen M, et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun [Internet]. 2016;74:94–105. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896841116300920
- Little J, Parker B, Lunt M, et al. Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort. Rheumatology [Internet]. 2018;57(4):677–687. Available from: https://academic.oup.com/rheumatology/article/57/4/677/4817410
- Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins lupus cohort. Lupus Sci Med [Internet]. 2015;2(1):e000066–e000066. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2014-000066
- Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis [Internet]. 2022;81(1):100–107. Available from: https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2021-220920
- Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med [Internet]. 2020;383(12):1149–1155. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2023325
- Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-bdca2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med [Internet]. 2022;387(10):894–904. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2118025
- Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med [Internet]. 2022;28(10):2124–2132. Available from: https://www.nature.com/articles/s41591-022-02017-5
- Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a Tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized,double-blind, placebo-controlled trial. Arthritis Rheumatol [Internet]. 2023;75(2):242–252. Available from: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.42391
- Lockshin MD, Barbhaiya M, Izmirly P, et al. SLE: reconciling heterogeneity. Lupus Sci Med [Internet]. 2019;6(1):e000280. Available from: https://lupus.bmj.com/lookup/doi/10.1136/lupus-2018-000280
- Mok CC, Teng YKO, Saxena R, et al. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat Rev Rheumatol [Internet]. 2023;19(4):227–238. Available from: https://www.nature.com/articles/s41584-023-00925-5
- Gordon C, Wofsy D, Wax S, et al. Post hoc analysis of the phase ii/iii april‐SLE study: association between response to atacicept and serum biomarkers including blys and APRIL. Arthritis Rheumatol [Internet]. 2017;69(1):122–130. Available from:https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.39809
- Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun [Internet]. 2021;12(1):3391. Available from: https://www.nature.com/articles/s41467-021-23361-z
- Gatto M, Zen M, Iaccarino L, et al. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol [Internet]. 2019;15(1):30–48. Available from: https://www.nature.com/articles/s41584-018-0133-2